VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
ANROAlto Neuroscience, Inc.$21.47$753M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksANROEarnings History

ANRO logoAlto Neuroscience, Inc. (ANRO) Earnings History

Net Loss

5 years of earnings data (2021–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$74M
● Net Loss
TTM EPS (Diluted)
$-2.26
Per share, diluted
YoY EPS Growth
+12.4%
Strong
Net Margin
N/A
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating MarginN/A
Gross MarginN/A
Return on Equity-41.8%
Return on Assets-34.9%
Record Annual Net Income-$9MFY2021
Record Quarterly EPS$-0.34Q3 2023
Consecutive Profitable Years0years
Q1 2026
Net Income-$26M
EPS (Diluted)$-0.80
YoY Growth+12.4%Strong
QoQ Growth-62.1%Declining

Loading earnings history...

Alto Neuroscience, Inc. (ANRO) Earnings Overview

As of June 13, 2026, Alto Neuroscience, Inc. (ANRO) reported trailing twelve-month net income of -$74M, reflecting +12.4% year-over-year growth. The company earned $-2.26 per diluted share over the past four quarters.

Looking at the long-term picture, ANRO's historical earnings data spans multiple years. The company achieved its highest annual net income of -$9M in fiscal 2021.

Alto Neuroscience, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including SAVA (-$106M net income), NRXP (-$25M net income, -2336.5% margin), INVA ($504M net income, 63.8% margin), ANRO has comparable earnings metrics. Compare ANRO vs SAVA →

ANRO Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
ANRO logoANROCurrent
-$74M$-2.26--41.8%+12.4%—
SAVA logoSAVA
-$106M$-2.20--17.2%+77.6%
NRXP logoNRXP
-$25M$-0.76-2336.5%-+43.9%
INVA logoINVA
$504M$5.9463.8%29.1%+816.7%
ACAD logoACAD
$376M$2.1836.5%39.9%+68.4%
AXSM logoAXSM
-$188M$-3.68-28.7%-252.1%+38.6%
Best in group
Lowest in group

ANRO Historical Earnings Data (2021–2025)

5 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$63M-2.9%-$66M$-2.19--
2024-$61M-69.2%-$69M$-2.50--
2023-$36M-31.0%-$38M$-1.35--
2022-$28M-201.6%-$29M$-1.08--
2021-$9M--$12M$-0.36-4374.8%-5741.0%

Download Data

Export ANRO earnings history in CSV or JSON format

Free sign-in required to download data

What if you invested $1,000 in ANRO back in 2021?

Total return with dividends reinvested · 5+ years of data

Calculate Returns

How much would $100/month in ANRO be worth today?

Dollar cost averaging vs lump sum · see how regular investing compounds over time

Run the Numbers

Is ANRO Undervalued Right Now?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

ANRO vs LLY — which is the better buy?

Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.

Compare Now

ANRO — Frequently Asked Questions

Quick answers to the most common questions about buying ANRO stock.

What is ANRO earnings per share (EPS)?

ANRO trailing twelve-month (TTM) diluted EPS is $-2.26, reflecting +12.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2021 to 2025 is available in the table on this page.

What is Alto Neuroscience, Inc.'s net income?

Alto Neuroscience, Inc. (ANRO) trailing twelve-month net income is $-74M as of 2025. Earnings grew +12.4% year-over-year.

Is ANRO profitable?

ANRO is not currently profitable on a TTM basis, reporting a net loss of $-74M. Net margin is N/A. Investors should monitor for a return to profitability.

What is ANRO's earnings growth rate?

ANRO compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2021 to 2025.

What are ANRO's profit margins?

Alto Neuroscience, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -41.8%.

Is ANRO growing earnings?

ANRO is growing earnings steadily. YoY EPS growth of +12.4% is consistent with the 5-year CAGR of N/A. TTM net income is $-74M.

What was ANRO's best earnings year?

Alto Neuroscience, Inc.'s highest annual net income on record is $-9M, achieved in fiscal year 2021. Earnings history on this page spans 2021 to 2025 and includes all annual and quarterly figures.

What were ANRO's earnings last quarter?

ANRO's most recent reported quarter was Q1 2026. Net income was $-26M with diluted EPS of $-0.80. For a full breakdown of all quarters, see the quarterly earnings table on this page.

ANRO Earnings Over Time (2021–2025)

Net income & EPS — annual and quarterly view